Newsletter · · Ashutosh Agarwal

Washington Tilts Pro Payer Then Targets Insurer Data - Managed Care Under Pressure - Week of July 25, 2026

Managed-care podcasts stayed quiet on Q2'26 earnings for the week of July 25, 2026, while Washington handed payers a surprise-billing cost tailwind and then moved to force open their claims and drug-pricing data.

Managed Care Under Pressure

Week of July 25, 2026: Washington Tilts Pro Payer Then Targets Insurer Data

Quiet on earnings; Washington tilts pro-payer, then targets their data

TL;DR

  • The earnings vacuum is real. Q2'26 managed-care reporting season is live, CVS, HUM, ELV, CNC and MOH all report over the next couple of weeks, yet not a single podcast this week covered a managed-care print or preview. The only equity-desk voices are still talking about UnitedHealth (UNH), a week and a half after its beat. Take specific stock calls this week as sentiment, not fresh news.
  • The real story moved to Washington. New CMS data shows the surprise-billing arbitration system cost roughly $15 billion in 2025, up from $4 billion in 2024, and the government is now siding with insurers who say the system is being gamed. That is a genuine tailwind for commercial medical costs. The catch: Congress is simultaneously advancing bills to hand employers and PBMs full access to insurers' claims and drug-pricing data, a direct hit to the payers' core competitive advantage.
  • The 2027 Medicare setup keeps firming up. The 2027 MA advance notice landed a few weeks ago and is being described as "pretty favorable" for the industry, and CMS is bringing a medication-review quality measure back into Star ratings for 2027, another quiet positive for the funding-and-margin recovery story into next year.

What's New

1. The surprise-billing fight has flipped in the insurers' favor, and it is a real cost tailwind. On the Becker's Healthcare Podcast (July 24), payer reporter Jakob Emerson (journalist) walked through brand-new CMS data on the No Surprises Act's arbitration process, the federal system where out-of-network providers and insurers fight over how much a bill gets paid. His words: the process "has reached almost $15 billion in costs in 2025 alone. That compares to $4 billion in 2024. So the costs have exploded." Providers, air-ambulance firms and the billing companies they hire have flooded the system with disputes, and insurers, UnitedHealthcare among them, are now openly complaining on earnings calls that it is driving up commercial costs. Crucially, the administration is taking the payers' side: a CMS spokesperson told The Wall Street Journal the system "is being gamed to get higher prices, and CMS is actively working to clean it up." Emerson expects "some rulemaking, some reforms over the next year or so." Why it matters: out-of-network cost pressure has been a quiet drag on commercial medical loss ratios (MLR, the share of premium dollars paid out as medical claims). If Washington reforms the arbitration system in payers' favor, that helps the commercial books at UNH, ELV, CVS/Aetna and CI.

2. …but the same week, Congress moved to pry open the payers' black box. In the same Becker's Healthcare Podcast conversation, Emerson flagged health-care packages that advanced out of committee this week to codify hospital and payer price-transparency rules, and, in the Senate version, a provision that would give employers, third-party administrators and PBMs "legal rights to their claims data and reimbursement formulas around prescription drugs." He gave a concrete example: a large employer like Kraft Heinz suing its administrator (an Aetna or a United) to get the full claims data on what it is being charged. His read: "the negotiating power of the payers just keeps getting worse over time… Congress is signaling they want to… go after the leverage or really the entire infrastructure of how the insurer and claims and pricing structure of the healthcare system is built." Why it matters: claims-data opacity is how insurers and PBMs defend their margins. Forced transparency is a slow, structural negative, most acute for the PBM arms (CVS's Caremark, UNH's OptumRx, CI's Express Scripts).

3. UnitedHealth is still the only managed-care name the money managers will touch out loud. On CNBC's Halftime Report (July 21), portfolio manager Stephanie Link (buy-side) used her final trade to repeat last week's call: "UnitedHealthcare. The CEO is doing his job in turning around the company. The turnaround is happening. They just guided to $20 a share and the stock is cheap and it should be bought." And on Mad Money (July 20), Jim Cramer (pundit) admitted the rebound stung to watch: "That United Health made me want to kick myself." Why it matters: this is the tell of the week, the sector's re-rating is still a one-stock story. Two-plus weeks after the print, active managers are anchoring to UNH's raised FY26 adjusted EPS guide of $19.50–$20.00 and nobody is yet putting a fresh stake in CVS, HUM, ELV, CNC or MOH ahead of their prints.

4. The 2027 Medicare picture keeps improving at the margin, including on Star ratings. On the Pharmacy Podcast Network (July 22), Outcomes' Ross Frey and Cindy Hendry (industry) noted that the 2027 MA advance notice, out "a couple of short weeks ago," formalizes CMS's intent to bring the Comprehensive Medication Review (CMR) completion rate back as a Star ratings measure for measure-year 2027, with a growing denominator (plans will have to review more members). Star ratings drive the quality-bonus payments that fund richer MA benefits, so plans are, in their words, in a "precarious" spot re-planning their Star strategies. This dovetails with Emerson's separate observation that the 2027 rate notice "was pretty favorable for the industry." Why it matters: the funding backdrop for 2027 MA, the year the bulls are underwriting for a margin recovery, keeps getting incrementally better, even as the quality bar (and the cost of clearing it) rises.

5. Hard new numbers on the GLP-1 cost problem, employers are containing it, not eliminating it. On Talking Benefits (July 22), the International Foundation of Employee Benefit Plans reviewed a new survey of 300-plus U.S. employers (fielded June 2–12, 2026). Among employers that cover GLP-1 weight-loss drugs (Wegovy, Zepbound), those drugs were 11.4% of total claims costs in 2025, up from 10.5% in 2024, and 26% of employers said GLP-1s topped 15% of all claims spending. But coverage is not expanding: 60% of employers still cover GLP-1s for diabetes only (up from 55% a year ago) and just 36% cover them for weight loss (flat year-over-year), while the tools around them tightened: 95% now require prior authorization, 79% use utilization management and 90% impose a minimum-BMI threshold. Separately, Diabetes Connections (July 21) confirmed Medicare Part D coverage of GLP-1s for eligible patients went live on July 1. Why it matters: the commercial GLP-1 hit is rising in dollars but being aggressively managed, while the Medicare door is now open, the mixed cost picture that keeps this a swing factor for 2026–27 medical trend.

The Debate

Bull: the worst is priced, and 2027 is set up to heal. UNH's Q2'26 print (MLR down about 320 basis points year-over-year to 86.2%, guidance raised for a second time to $19.50–$20.00) said the utilization spike is being repriced out. The 2027 setup is quietly constructive: a "favorable" advance notice, and now Washington leaning toward insurers on surprise-billing costs, a genuine commercial-MLR tailwind if arbitration reform follows. At roughly 17x earnings, the group's biggest name still trades below its historical low-20s multiple, and the one buy-side voice on the podcasts this week is still saying "buy it."

Bear: this is a one-quarter, one-stock rally on top of a structural reset. No one has bought the rest of the group for a reason: CVS, HUM, ELV, CNC and MOH still have to prove Q2 wasn't a UNH-specific execution story. The structural pressures are all still live: forced claims-data transparency erodes payer and PBM leverage over time; the ACA subsidy cliff and Medicaid work requirements are shrinking and sickening the exchange and Medicaid pools that CNC, MOH and ELV depend on; GLP-1 costs keep climbing as a share of claims; and Star-ratings litigation and the return of quality measures raise the cost of the bonus payments the bull case is counting on. A "favorable" rate notice does not undo a multi-year margin reset.

Stocks in Play

Reminder: no company reported this week and no podcast discussed a Q2'26 print for anyone but UNH. The cases below carry forward last week's setup, updated only where this week's coverage adds something real.

  • UNH: Bull: Q2'26 beat-and-raise (MLR 86.2%, FY26 EPS guide $19.50–$20.00), still the only name money managers will publicly buy (Stephanie Link, Halftime, July 21). A win on surprise-billing reform helps its commercial book. Bear: owns OptumRx, squarely in the claims-data-transparency crosshairs; also the loudest voice complaining about arbitration costs, which cuts both ways politically. Next catalyst: whether the +YTD move holds as peers report; any DOJ MA-coding or RADV headlines (none this week).
  • CVS: Bull: Caremark and pharmacy cushion Aetna; the 2027 MA/Star setup is firming. Bear: Caremark is the biggest single target of the price-transparency and claims-data push; Aetna carries the same MA cost and Star exposure. Next catalyst: Q2'26 Aetna medical benefit ratio (MBR) and any 2027 benefit-design color when it reports in the coming weeks.
  • HUM: Bull: most MA-levered name into a "favorable" 2027 notice and improving Star measures; absorbs members from exiting regional plans. Bear: highest concentration of MA cost and Star-ratings risk. Next catalyst: Q2'26 MCR and whether its membership-growth guide carries margin.
  • ELV: Bull: Carelon plus 2027 repricing; still the plaintiff in the CMS Star-ratings suit that could restore ~$115M. Bear: directly exposed to the ACA subsidy cliff and Medicaid attrition described this week (see read-throughs). Next catalyst: Q2'26 Medicaid and MA cost splits; any movement in its CMS lawsuit (none surfaced this week).
  • CNC: Bull: exchange and Medicaid scale if pricing holds. Bear: the subsidy cliff hits its book hardest: shrinking, sicker exchange pools and ~14% proposed 2027 marketplace rate increases. Next catalyst: Q2'26 health benefits ratio (HBR) by segment and 2027 exchange enrollment. (Read-through only this week.)
  • MOH: Bull: disciplined Medicaid underwriting. Bear: most Medicaid-levered into work requirements and coverage losses now taking hold. Next catalyst: Q2'26 MCR and RFP wins/losses. (Read-through only this week.)
  • CI: Bull: Evernorth/Express Scripts growth; already out of MA, so no MA cost or Star exposure. Bear: Express Scripts sits inside the same PBM-transparency and claims-data frame as Caremark and OptumRx. Next catalyst: Q2'26 Evernorth growth and any response to the transparency legislation.

Read-throughs

  • Medicaid and exchange insurers (CNC, MOH, ELV). The policy squeeze got fresh, on-the-ground color. On An Arm and a Leg (July 23), KFF Health News Chief Washington Correspondent Julie Rovner (policy) described the human version of the numbers: Congress "added work requirements to Medicaid" and "allowed federal subsidies for Obamacare to expire for millions." Many enrollees whose subsidies fell "bought down into less generous policies, and now they have 5-figure deductibles… so they have insurance, but they still can't afford to get care." That is the dynamic that shrinks enrollment and worsens the risk pool for the Medicaid and exchange-heavy insurers. It lines up with the roughly 14% 2027 marketplace rate increases insurers have proposed, referenced this week on Unf*cking The Republic (July 22).
  • PBMs and Optum-style services arms (Caremark, OptumRx, Express Scripts). Two forces converged this week: the claims-data legislation Emerson described, and continued momentum behind transparent PBM models. On The Benefits Playbook (July 23), SmithRx founder and CEO Jake Frenz (operator) laid out the traditional model's pressure points: 90%-plus discounts off inflated average wholesale prices on generics, and a rebate "black box" where PBMs earn on rebate retention and retail spread. He argued the PBM should be a conflict-free "co-fiduciary." The direction of travel, from both Congress and the market, is toward transparency, and that is a slow grind against the profit pools inside CVS, UNH and CI.
  • Hospitals and providers. The surprise-billing reversal is the mirror image of the payer tailwind: providers and their billing agents have been the winners of the arbitration system, and CMS moving against it is a provider negative. Separately, on the Becker's Healthcare Podcast (July 24), Bridge Oncology's Jordan Johnson flagged that CMS's 2027 proposed rules keep pushing site-neutral payments and "total cost of care" over volume, another squeeze on provider reimbursement that, at the margin, favors the payers on the other side of the table.
  • GLP-1 cost exposure. The employer survey above (Talking Benefits) is the cleanest read: GLP-1s are now 11.4% of claims for employers that cover them, but coverage is being rationed hard (95% prior authorization, minimum-BMI gates, diabetes-only for the majority). With Medicare Part D coverage now live as of July 1, the cost question shifts toward the government book even as commercial plans hold the line.

What Changed vs Last Week

  • The equity-desk conversation narrowed. Last week UNH's beat pulled the whole sector onto general-market podcasts; this week the earnings coverage went quiet again even though Q2'26 season is live. Stephanie Link simply repeated her "buy UNH" call; no one added a new name.
  • A genuinely new policy vector appeared. The No Surprises Act arbitration data ($15B in 2025 vs $4B in 2024) and the price-transparency/claims-data legislation are both new this week and cut in opposite directions: near-term cost relief, longer-term leverage erosion.
  • The 2027 Star-ratings mechanics got more specific. Last week was about the Elevance suit and the bonus pool; this week added the return of the CMR quality measure for 2027 and confirmation the advance notice reads "favorable."
  • GLP-1 went from anecdote to data. Last week gave us the Medicare bridge pricing; this week added hard employer cost shares (11.4% of claims) and confirmation Part D coverage is live.
  • Still absent (now seven weeks running): a dedicated buy-side or sell-side healthcare-investing podcast; any investor-desk quantification of V28 or RADV; movement on the Elevance-CMS Star suit; UNH's DOJ MA-coding probe; and M&A chatter (Optum carveout, CVS strategic review, Humana Medicaid sale). And, notably this week, zero podcast coverage of any Q2'26 print for CVS, HUM, ELV, CNC, MOH or CI.